← Zentalis Pharmaceuticals, Inc. (ZNTL) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Zentalis Pharmaceuticals, Inc. (ZNTL)
Pharmaceutical Preparations · market cap $209M · as of 2026-07-10
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-23
Conference
Pipeline
4
programs
Upcoming events
3
next 90d+
Dossier
Ready
cached
Zentalis Pharmaceuticals (ZNTL) is a small-cap oncology/rare-disease biotech with a market cap of ~$346M and a pipeline spanning four Phase 2 assets across ovarian cancer, uterine serous carcinoma, and amyloidosis. The company reported zero revenue in 2025, burned $107M in R&D that year, and holds only $31.9M in cash — implying a runway of roughly 2.9 months as of mid-2026. A near-term financing event appears virtually certain.
The catalyst path
- 2026-10-23Conferenceimp 3/10
- 2026-11-09 (est.)Earningsimp 5/10
- 2026-12-01 (est.)Phase 2 · azenosertibimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| ZN-d5 | Phase 2 | Amyloidosis |
| Niraparib | Phase 2 | Ovarian Cancer |
| azenosertib | Phase 2 | High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer |
| ZN-c3 | Phase 2 | Uterine Serous Carcinoma |
Price & technical context
3-month
-41.5%
6-month
+1.6%
12-month
+72.8%
52-wk range
$1.28–$6.61
vs 50-day MA
-31.2%
vs 200-day MA
-23.5%
Realized vol
117.1%
Max drawdown
-76.1%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ZNTL (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.